Nuclear Medicine News
-
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100) to Improve Heart Failure Outcomes & Reduce Costs
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be featured in a MedAxiom Academy webinar – Best Practices for Using Blood Volume Analysis to Reduce Heart Failure LOS, Readmissions, Mortality and Costs on November 17, 2022, at 1pm ET. This live webinar will take a deep dive into the best ...
-
ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177
An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM), announced today the commencement of commercial production of lutetium-177. The announcement was celebrated at ITM’s headquarters in Munich, Germany, along with representatives of the partnership organizations during a trade mission with Vic Fedeli, ...
-
CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences
The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business meetings in June and one that took place in April, the company announced in a press release. The meetings featuring CTT presentations include the American Society of Clinical ...
-
Prof. Krestin Joins Fluidda’S Board of Directors
INTRODUCTION Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked at the University Hospital in Zürich/CH, including a period as acting chairman of the Department of Radiology. In 1997 he moved to Erasmus MC in Rotterdam, Netherlands where he was the ...
By Fluidda
-
Betaglue technologies strengthen its expertise in strategic areas with four new managers
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Caia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated Milan, October 19, 2022 - BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, ...
-
Meet us at the WMIC 2022, September 28 - October 1 in Miami, Florida, USA
Check out the advantages that our specialized imaging agents can provide to your research! Come and visit at the World Molecular Imaging Congress (WMIC) 2022 in Miami to discover our innovative range of Viscover products and their exciting application possibilities. We look forward to seeing you to discuss your diagnostic imaging needs and to share the latest experiences in pre-clinical ...
-
BetaGlue has enrolled the first patient treated with BAT-90 in its First-in-Human trials, taking radiotherapy inside solid tumours
The first clinicalfindingshave shown that BAT-90makes it possible to treat onlythe area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy and patient safety BetaGlue Technologieshasenrolledthe first patientin a clinical trialwithBAT-90, the company’s cancer radiotherapy platform. The first clinical findings have shown thatBAT-90 ...
-
Betaglue technologies: closing of a eur 10 million financing round
Fin Posillipo (Petrone Group], Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaoh Group), Profequycapital and Romedjoined the share capital Innogest Capital and Panakes Partners reinvest The financing will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, and accelerate access to the Safe-Biopsy Device market, thus opening a new chapter in ...
-
FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the 2022 SNMMI Image of the Year Award and JNM Editors’ Choice Award for Overall Best Article in 2021, respectively. Both use FAPI as the primary indicator and further underscore its potential impact as a novel radiopharmaceutical. Each year, SNMMI chooses an image that best ...
By SOFIE
-
Betaglue takes radiotherapy inside solid tumours: first patient treated
The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the pre-clinical studies with BAT-90 opens ...
-
Akrotome Co-Founder Makes International Presentations
Akrotome Co-Founder, Dr. Jim Basilion, traveled to Europe to make invited presentations in November, 2018. Dr. Basilion delivered papers focused on the use of molecular probes for guided, precision surgery to the European Society of Molecular Imaging, the World Society of Molecular Imaging, and the Netherlands Science ...
-
Edinburgh Molecular Imaging and Mauna Kea Technologies Announce Clinical Molecular Imaging Collaboration
Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser endomicroscopy platform to diagnose cancer. The combination of novel molecular imaging agents and advanced visualisation ...
-
Zionexa us corp. Secures pass-through payment status and assignment of temporary c-code for cerianna
Zionexa US Corp., a wholly owned subsidiary of Zionexa SAS, specialized in the development and commercialization of in-vivo biomarkers for use in guiding targeted therapies in oncology, announced that the Center for Medicare and Medicaid Services (CMS) has approved transitional pass-through status and reimbursement through a C-code for Cerianna (fluoroestradiol F-18) injection. Cerianna ...
By Zionexa
-
Blue Earth Diagnostics Appoints Dr. David E. Gauden as Chief Executive Officer and Dr. Eugene J. Teoh as Chief Medical Officer
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of David E. Gauden, D.Phil. as its new Chief Executive Officer (CEO). Former CEO and Executive Chairman Jonathan Allis, D.Phil., assumes the role of Honorary Chairman of the Blue Earth Diagnostics Board of Directors. Dr. ...
-
Positron Corporation Retains FDA Consulting Firm in Preparation for 510K New Device Application
Niagara Falls, NY – February 17, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce today that the Company has retained Medical Device Academy ”MDA”) as its consultant for the Company’s new PET/CT device 510K ...
-
Positron Enters Long Term Cooperation Agreement with Neusoft Medical Systems
Positron Enters Long Term Cooperation Agreement with Neusoft Medical Systems for the Development and Distribution of Positron’s State of the Art PET/CT System in North America Niagara Falls, NY – January 18, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging company specializing in the field ...
-
Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet and using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/34857658/). The phase II study The phase II trial (NCT02965001) aimed to ...
By Curasight
-
MOBILion and International Research Team are Awarded Grant from The Michael J. Fox Foundation and the Shake it Up Australia Foundation to Resolve Biomarkers for Parkinson’s Disease
MOBILion Systems, Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development, is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in specific brain regions that contribute to the early onset and progression of Parkinson’s disease. The ...
-
Profacgen Enables Custom Bioinformatics Software Development for Researchers Worldwide
Profacgen, a US-based biotechnology company, recognizing the importance of computational technologies for pursuing advanced research in modern biology, released custom bioinformatics software development to offer support for both academic and industrial researchers to explore, understand and analyze complex biological data in a variety of biotechnology programs and projects. Bioinformatics ...
By Profacgen
-
The MALDI-Imaging Lipidomics Service Is Now Available Through Lipidomics Platform
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The company has recently announced the fully-developed MALDI-Imaging Lipidomics Service to research the distribution of lipids in tissues. Lipidomics MALDI imaging mass ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you